 ​American College of Cardiology (ACC) conference highlights- March 29-31, 2025

<p>ACC 2025 Conference held in Chicago from March 29–31, spotlighted major advancements in cardiovascular care. The SOUL trial confirmed oral semaglutide’s ability to reduce cardiovascular events in high-risk type 2 diabetes patients. The STRIDE trial showed GLP-1 therapy improved walking capacity in diabetic PAD patients. Meanwhile, PROTECT-TAVI results cast doubt on routine embolic protection during TAVI, while other notable studies explored novel siRNA agents (ALPACA), AI in myocardial infarction detection, and optimized antiplatelet strategies post-PCI.</p>

​American College of Cardiology (ACC) conference highlights- March 29-31, 2025

American College of Cardiology (ACC) conference highlights- March 29-31, 2025